Bioavailability of SPMs in Obese Humans

Inclusion Criteria: * 24 (n=12 male + 12 female) obese (BMI 30-40 kg/m\^2) subjects with age 50-65 years who are euglycemic and pre-diabetic (i.e. fasting glucose 70-125 mg/dL or HbA1c of 5.7-6.4%). * Only post-menopausal females will be recruited in the female cohort to reduce the confounding effects of estrogen on lipid metabolism during supplementation. Exclusion Criteria: * Those with fasting glucose values \> 126 mg/dL or known type 2 diabetes * Females who are pre-menopausal, pregnant, planning to become pregnant, breastfeeding or lactating * Subjects consuming n-3 PUFA supplements in the last 3 months prior to enrollment, high consumption of fatty fish (\>2 servings per week), and subjects with active autoimmune disease, liver disease, coagulopathy, hypothyroidism, known allergy to fish or shellfish, inability to give informed consent, or taking anticoagulants (e.g. warfarin and direct-acting anticoagulants), those taking estrogen or testosterone, and anyone taking daily aspirin, NSAIDs, or active asthma medications. * Subjects receiving immunomodulatory or immunosuppressant therapy (corticosteroids or monoclonal antibodies) in the 4 weeks prior to study enrollment, and subjects with known active malignancy or undergoing treatment for malignancy will be excluded. * Subjects who test positive for COVID-19 or have tested positive in the past will be excluded. Those who report COVID-19 or flu-like symptoms will be excluded, as well as those that fail to pass COVID-19 s…